新闻
CBAY
--
0.00%
--
过氧化物酶体增殖物激活受体三角洲市场规模,份额,增长,趋势,COVID-19分析和预测2021-2028
Comserve · 1天前
全球免费脂肪酸受体4 Professional规模,份额,价值和竞争格局2020
May 07, 2021 (Heraldkeepers) -- Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional...
Heraldkeepers · 1天前
纯合子家族性高胆固醇血症治疗市场规模2021:行业趋势,新兴技术,增长因素,到2027的发展和预测
May 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The Global "Homozygous Familial...
The Express Wire · 1天前
顶级分析师表示,十只“强力买进”的医疗保健股具有超过100%的上涨潜力
TipRanks.com · 04/27 13:58
原发性胆汁性肝硬化药物市场2021年研究和临床分析-AlbireoPharma(NASDAQ:LBO),CymaBay Therapeutics,MediGene AG,NGM Biopharmaceuticals
Apr 26, 2021 (Market Insight Reports) -- Global Primary Biliary Cirrhosis Drug Market Size, Status and Forecast 2021 The Global Primary Biliary Cirrhosis...
Market Insight Reports · 04/26 09:54
按产品类型划分的2021年葡萄糖依赖性促胰岛素受体市场,到2027年销售额,收入,价格,市场份额和增长率
The Express Wire · 04/21 10:44
全球原发性胆汁性肝硬化药物市场洞察,概述,分析和预测2021-2026
Apr 20, 2021 (Heraldkeepers) -- The Primary Biliary Cirrhosis Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/20 08:25
全球纯合子家族性高胆固醇血症治疗市场前景,行业分析和前景2021-2026
Apr 15, 2021 (Heraldkeepers) -- COMTEX_384481072/2582/2021-04-15T07:59:11 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 04/15 11:59
全球高甘油三酯血症治疗市场规模,份额,价值和竞争格局2024。
Apr 15, 2021 (Heraldkeepers) -- Research ScopeThis report researches the worldwide Hypertriglyceridemia Treatment market size (value) in key regions like...
Heraldkeepers · 04/15 05:32
痛风疾病治疗市场报告发布行业预测趋势
Apr 14, 2021 (Market Insight Reports) -- Global Gout Disease Treatment Market Gout is a severe medical condition characterized by formation of excess of uric...
Market Insight Reports · 04/14 11:20
游离脂肪酸受体4市场研究报告(按类型,产品和应用分类)-到2027年的全球预测-COVID-19的累积影响
Market Insight Reports · 04/07 10:26
Brief-CymaBay任命托马斯·威根斯(Thomas Wiggans)和珍妮特·多林(Janet Dorling)担任董事会成员
reuters.com · 04/05 12:17
新闻稿:CymaBay任命Thomas Wiggans和Janet Dorling担任董事会成员
Dow Jones · 04/05 12:00
2020年全球游离脂肪酸受体4市场规模,份额,价值和竞争格局
Apr 05, 2021 (Heraldkeepers) -- Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional...
Heraldkeepers · 04/05 09:51
具有主要国家/地区的数据行业规模,份额,业务增长,收入,趋势,市场需求渗透率和预测的全球原发性胆汁性肝硬化药物市场2021-2027 |使用Covid-19分析
The Express Wire · 04/05 05:03
奥本海默重申对CymaBay Therapeutics(CBAY)的买入评级
Oppenheimer analyst Jay Olson maintained a Buy rating on CymaBay Therapeutics (CBAY) today and set a price target of $14.00. The company's shares closed
SmarterAnalyst · 03/26 19:25
B.Riley Financial重申对CymaBay Therapeutics(CBAY)的买入评级
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on CymaBay Therapeutics (CBAY), with a price target of $13.00.
SmarterAnalyst · 03/26 17:35
CymaBay Therapeutics(CBAY)连续第三次购买
After Piper Sandler and Oppenheimer gave CymaBay Therapeutics (NASDAQ: CBAY) a Buy rating last month, the company received another Buy, this time from
SmarterAnalyst · 03/26 13:25
分析师提供有关医疗保健公司的见解:CymaBay Therapeutics(CBAY),ADMA Biologics(ADMA)和Brainsway(BWAY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CymaBay Therapeutics (CBAY), ADMA Biologics (ADMA) and
SmarterAnalyst · 03/26 11:25
DJ Cymabay Therapeutics,Inc.首席执行官Sujal Shah关于2020年第四季度业绩-收益电话抄本> CBAY
Dow Jones · 03/26 05:47
微牛提供丰富的实时CBAY股票新闻,让你可以通过多个平台了解CBAY股票行情最新动态,这些免费的CymaBay新闻可以帮助你做出明智投资。
CBAY 简况
CymaBay Therapeutics Inc是一家临床阶段的生物制药公司。该公司致力于开发治疗代谢性疾病的疗法,包括严重的罕见病和孤儿病。其药物管线包括Seladelpar、MBX-2982和CB-001。该公司的主要候选产品seladelpar是过氧化物酶体增殖物激活受体δ(PPARd)的有效选择性激动剂,是一种核受体,可直接或间接调节胆汁酸/固醇的合成,脂质和葡萄糖的代谢,炎症和纤维化。PPARd受体是一种核受体,调节与胆汁酸/固醇,脂质和葡萄糖代谢有关的基因以及某些炎症细胞。Seladelpar专注于治疗某些肝脏疾病和多种脂质代谢紊乱。